Rethinking India’s cancer-care infrastructure

Dr Sanket Mehta, Founder & CEO, SSO Cancer Hospitals, discusses investment opportunities in surgical oncology, expanding specialised cancer care beyond metros, and the role of robotic surgery and indigenous medical-device innovation in an interview with Swati Rana

India’s oncology sector is witnessing growing demand for specialised cancer care. What are the biggest investment and infrastructure opportunities in surgical oncology, and what challenges must healthcare providers overcome to build scalable, sustainable cancer-care models? 

The biggest opportunity is not simply to build more hospitals; it is to build centres that can deliver complex cancer surgery consistently and at viable costs. India had about 1.41 million new cancer cases in 2022, IARC said. But investment in infrastructure must go beyond the operating theater and embrace specialist surgeons, critical care, advanced pathology, and reliable referral pathways. 

The commercial challenge is balancing high fixed costs with appropriate patient volumes. Organ-specific centres offer one solution: concentrated expertise, standardised pathways and better utilisation of specialised resources. The winning model will combine clinical depth with disciplined operations, rather than scale through beds and buildings alone. 

CRS-HIPEC requires specialised infrastructure and skilled teams. How can hospitals make this treatment commercially sustainable and more accessible? 

CRS-HIPEC is a high complexity service, not a procedure that every hospital should attempt to offer. Its economics depend on selecting the right patients, maintaining an experienced team and managing the entire episode of care from surgery and intensive care to recovery. Low volumes can make infrastructure difficult to sustain; indiscriminate volumes can compromise patient selection. Hospitals should build referral relationships with oncologists across regions, establish clear eligibility protocols and track outcomes alongside costs. 

Affordability also requires structured packages and partnerships with public funding schemes or charitable trusts. The objective is to concentrate expertise where it can deliver results, while widening access to eligible patients. 

How can healthcare providers expand specialised cancer care into Tier II and Tier III cities without compromising quality? 

The mistake would be to replicate a metropolitan cancer hospital in every smaller city. That spreads scarce specialists and expensive equipment too thinly. A better approach is to decentralise access while concentrating expertise: establish local diagnostic and consultation services, develop selected surgical capabilities where teams and support infrastructure are ready, and connect complex cases to established centres. 

. The model must specify which procedures can be performed locally and which require referral. Shared protocols, specialist mentoring, pathology quality assurance and outcome audits are essential. Expansion should follow clinical capability, not market demand alone. Patients should gain proximity without being asked to accept a lower standard of care.

As Founder and CEO of SSO Cancer Hospitals, how do you balance clinical excellence, operational efficiency and financial sustainability? 

I start with a simple principle: financial discipline should remove waste, not influence which treatment a patient clinically needs. In oncology, the right specialist, the right diagnosis and the right sequence of treatment can prevent costly delays and inappropriate interventions. At SSO, our organ-specific model aligns expertise around the cancer being treated, rather than relying on a generalised surgical approach. 

Operationally, that means building focused teams, coordinating treatment decisions and using infrastructure efficiently. We also have to be realistic about affordability and the financial pressures patients face. A sustainable cancer hospital must deliver sound clinical outcomes, manage resources responsibly and remain accessible to the people it exists to serve. 

Robotic surgery is gaining momentum in oncology. How should hospitals evaluate its costs, clinical benefits and return on investment? 

A robot should earn its place in the operating theatre through clinical value, not marketing appeal. Before investing, a hospital must identify the specific cancer procedures where robotic surgery may offer an advantage over conventional laparoscopy or open surgery. It should model the complete cost: acquisition, annual maintenance, instruments, training, operating time and realistic case volumes. The clinical assessment must examine outcomes that matter: complications, recovery, functional preservation and length of stay, not merely the number of robotic procedures performed. 

Hospitals should also consider whether patients can afford the additional cost. If the clinical benefit is unclear or utilisation is unrealistic, the investment may not be justified. 

What opportunities exist for Indian medical-device manufacturers to develop cost-effective technologies for advanced cancer surgery? 

Indian manufacturers should focus on solving expensive, everyday surgical problems rather than attempting to reproduce every high-cost imported platform. Opportunities exist in advanced laparoscopic instruments, energy devices, surgical visualisation, navigation, reconstruction tools and components that are easier to maintain locally. 

The critical gap is not just product development; it is clinically informed design, validation and adoption. Surgeons need to be involved early so that devices address real procedural needs. Manufacturers must demonstrate safety, reliability and performance against accepted standards, while building service and training capabilities. Hospitals, in turn, should evaluate devices on clinical utility and total cost of ownership. Affordable innovation succeeds when it earns trust in the operating room. 

Can the hub-and-spoke model make specialised oncology commercially viable in smaller cities? What partnerships are needed to scale it? 

Yes, but only if the hub-andspoke model is designed around a clear division of clinical responsibility. The hub should concentrate complex surgery, subspecialist expertise and difficult multidisciplinary decisions. Spokes should provide services they can safely deliver early evaluation, diagnostics, selected treatments and follow-up with defined escalation pathways.

This can extend the hub’s reach without every place having to duplicate expensive infrastructure. Scaling will require formal partnerships with local hospitals, diagnostic providers, referring doctors, insurers and government health schemes. Shared records, referral timelines and outcome accountability are a must. The business case is based on co-ordinated patient flow and better utilization, not just a shifting of patients from one facility to another. 

Where are the biggest gaps in India’s oncology value chain, and where can private healthcare companies make the greatest impact? 

The most consequential gaps occur between stages of care: a suspicious finding may not lead to timely diagnosis; a confirmed diagnosis may not translate into treatment; and treatment may be disrupted by cost or travel. Adding tertiary beds alone will not solve these failures. Private providers can make a measurable difference by strengthening diagnostic pathways, developing regional specialist networks, publishing outcomes and helping patients navigate financing.

They can also create referral systems that connect community doctors with the right subspecialists earlier. The opportunity is to reduce the time, cost and uncertainty between suspicion and treatment. That requires investment in coordination as much as investment in clinical infrastructure. 

How can hospitals collaborate with pharmaceutical companies, medical-device manufacturers and research institutions to accelerate oncology innovation? 

Hospitals should bring industry partners real clinical questions, not just opportunities to introduce a product. For example, a surgical challenge may require a new instrument; an unmet treatment need may justify a clinical study; inconsistent outcomes may call for a shared registry. Funding, technology and scientific expertise can come from pharmaceutical companies, device makers and research institutions, while hospitals can provide clinical insight and appropriate research settings.

The arrangement shall have provisions for patient safety and scientific independence through ethics review, informed consent, transparent disclosures and publication safeguards. Success should be measured by evidence generated and patient benefit not the number of collaborations signed. Innovation is valuable when it changes clinical decisions or outcomes responsibly.

Which oncology segments offer the strongest growth opportunities over the next decade, and how should healthcare businesses prepare for them? 

I see strong opportunities in organ-specific surgical oncology, precision diagnostics, molecular pathology, minimally invasive and robotic procedures, and coordinated care beyond treatment. But the opportunity is not equally attractive everywhere; each segment requires different capabilities, capital and patient volumes. Businesses should first identify the unmet need in their target geography, then build the clinical team and evidence base before committing to expensive technology. 

Regional networks will also matter because specialised care cannot remain confined to major metropolitan centres. Finally, survivorship, rehabilitation and long-term monitoring need greater attention as more patients live beyond initial treatment. Sustainable growth will favour organisations that combine specialist expertise with credible outcomes and affordable delivery. 

swati.rana@expressindia.com

swatirana.express@gmail.com

cancer care infrastructure IndiaCRS-HIPEC treatmentoncology hospital investmentrobotic cancer surgerysurgical oncology
Comments (0)
Add Comment